Effects of three months ingestion of EBC extract (extract of an african plant) on body weight and adiposity.

ISRCTN ISRCTN94149868
DOI https://doi.org/10.1186/ISRCTN94149868
Secondary identifying numbers IRGA-01-2012
Submission date
19/07/2013
Registration date
23/04/2014
Last edited
02/05/2014
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Background and study aims
Obesity is one of the most important health problems in Western countries. Strategies are needed to reduce body weight. This study will assess whether an EBC extract (African plant) works on the body weight and the lipid profile of obese or overweight people.

Who can participate?
Males and females between 20 and 55 without any documented cardiovascular problems and with a body mass index between 27.5 and 34.9 Kg/m2

What does the study involve?
Participants are randomly allocated to one of three groups: EBC extract 75 mg, EBC extract 150mg or a dummy extract (placebo). There is a first visit and 3 follow-up monthly visits.

What are the possible benefits and risks of participating?
The benefits of participating will be weight loss and no risks are expected.

Where is the study run from?
Hospital Clínic of Barcelona, Spain.

When is study starting and how long is it expected to run for?
The study started in May 2013 and is expected to run for a year.

Who is funding the study?
Biocentury (Spain).

Who is the main contact?
Dr. Ramon Estruch
restruch@clinic.ub.es

Contact information

Prof Ramon Estruch
Scientific

Hospital CLínic de Barcelona
c/Villarroel nº170
Barcelona
08036
Spain
Barcelona
08036
Spain

Phone +34 93 2279365
Email restruch@clinic.ub.es

Study information

Study designOpen randomized and double blind placebo-controlled clinical trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleEffects of three months ingestion of EBC extract on body weight and adiposity.
Study objectivesThe benefit of the EBC extract will reduce at short term (3 months) body weight and fat body mass, as well as improve glucose metabolism parameters and lipid profile.
Ethics approval(s)This study has been approved by the Institutional Review Board of the Hospital Clínic of Barcelona.
Health condition(s) or problem(s) studiedOverweight and obesity
InterventionSubjects are randomized to three groups:
Group 1: Receives 4 capsules/day of placebo
Group 2: Receives 4 capsules/day of 75 mg each of EBC extract
Group 3: Receives 4 capsules/day of 150 mg each of EBC extract
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)EBC extract
Primary outcome measure1. Changes in body weight and body mass index
2. Changes in waist perimeter
3. Changes in fat body mass and distribution of fat in the body measured by DEXA (Dual-energy X-ray Absorptiometry)
Secondary outcome measures1. Medical record:
A complete medical record will be obtained from all participants, which included data on alcohol intake, smoking and dietary habits. Blood pressure and heart rate will be measured with an electronic apparatus Omron HEM-705CP (Netherlands).
2. Nutrition assessment, and general analyses :
All participants will complete 7-day dietary register during the week previous to the physical and laboratory assessment. We will assess the total quantity of calories ingested in the previous week as well as the proportion corresponding to carbohydrates, lipids and proteins by using the Food Processor Nutrition & Fitness software (esha RESEARCH, Salem, OR, USA) . Overall nutrition will be determined by percentage of ideal weight, lean body mass and body mass index. Waist Perimeter will be measured. The proteic nutrition will be determined on the basis of the following parameters: hemoglobin, total lymphocyte count, total proteins, albumin, prealbumin, transferrin and retinol-binding protein. Serum and intraerythrocytary folic acid concentrations will be measured, as well as serum vitamin A, B1, B12, C, E, B-carotenes, Zn, Mg and Se concentrations. Moreover, the following measurements will also be obtained: red blood cell count, hematocrit, mean corpuscular volume, leukocyte count, glucose, creatinine, electrolytes, uric acid, transaminases, lactate dehydrogenase, alkaline phosphatase, gammaglutamyl transpeptidase and bilirrubin. Physical activity will be measured using the Minnesota Leisure Time Physical Activity Questionnaire.
3. Plasma glucose and insulin concentration and Homeostasis Model Assessment (HOMA) will be determined.
4. Serum lipoproteins and others:
Total cholesterol, triglycerides, cHDL, cLDL, Apo A1, Apo B, and lipoprotein (a) will be determined.
5. Diet and exercise monitoring:
All participants will follow an isocaloric diet prepared according to their personal preferences. The diet will be strictly monitored during the study. Diet compliance will be assessed from 7-days diet records administered before each evaluation. This assessment will be administered by trained personnel. The foods ingested will be converted into nutritional values with the aid of the Professional Diet Balancer software (Cardinal Health Systems, Inc., Edina, MN). Physical activity will also be evaluated with the Minnesota Leisure Time Physical Activity questionnaire which has also been validated in Spain. Control of the diet and physical exercise will be carried out before and after each intervention, the same day on which the clinical examinations are performed and blood is withdrawn for immunologic studies.
Overall study start date19/05/2013
Completion date19/05/2014

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants120 participants (60 men and 60 women)
Key inclusion criteriaMales and females between 20 and 55 years old without documented cardiovascular disease (ischemic heart disease – angina or recent or old myocardial infarction or previous or cerebral vascular accident, peripheral vascular disease) and who have a body mass index between 27.5 and 34.9 Kg/m2.
Key exclusion criteriaSubjects with a previous history of cardiovascular disease (ischemic heart disease – angina or recent or old myocardial infarction, cerebral vascular accident, or peripheral vascular disease), any severe chronic disease, alcoholism or other toxic abuse will be excluded, as well as those subjects who had taken drugs or followed dietary interventions with potential effects on body weight in the last three months. Subjects who had changed their weight +/-3 kg in the last 3 months were also excluded from the study.
Date of first enrolment19/05/2013
Date of final enrolment19/05/2014

Locations

Countries of recruitment

  • Spain

Study participating centre

Hospital CLínic de Barcelona
Barcelona
08036
Spain

Sponsor information

Biocentury SLU (Spain)
Industry

Ctra. N-II km 71417242 Quart
Girona
17458
Spain

ROR logo "ROR" https://ror.org/02tx52885

Funders

Funder type

Industry

Biocentury SLU (Spain)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan